Additional small trials and patient series in RCC published since the TARGET trial.

Abbreviations: AE = adverse event; CI = confidence interval; CR = complete response; HFSR = hand foot skin reaction; NR = not reported; OS = overall survival; PFS = progression-free survival; PR = partial response; SD = stable disease.a All 39 pts for which results are posted received 2nd-line sorafenib.b Patients received either 1st-line sorafenib (n = 43), 1st-line sorafenib + IFN (n = 16), or 2nd-line sorafenib (n = 39).c Population who received 2nd-line sorafenib.d Subset of pts with RCC.e Results not reported individually for pts receiving single-agent sorafenib.f Not reached after 278 days mean follow-up.g Median (range).h Grade 1–2.Additional small trials and patient series in RCC published since the TARGET trial.